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Dual β-lactam combination 
therapy for multi-drug resistant 
Pseudomonas aeruginosa infection: 
enhanced efficacy in vivo and 
comparison with monotherapies of 
penicillin-binding protein inhibition
thanyaluck siriyong1,3, Rachael M. Murray1,2, Lucy E. Bidgood1, Simon A. Young  1,  
Florence Wright1, Benjamin J. parcell4, Supayang Piyawan Voravuthikunchai5 & 
Peter J. Coote1
The aim of the study was to determine the efficacy of dual β-lactam combination treatments derived 
from eight approved drugs against Galleria mellonella larvae infected with MDR strains of P. aeruginosa. 
Carbapenem-resistant P. aeruginosa NCTC 13437 and an unrelated clinical isolate were used to infect G. 
mellonella larvae and the efficacy of twenty-eight dual β-lactam combination therapies were compared 
to their constituent monotherapies. For the most potent combinations identified, penicillin-binding 
protein (PBP) inhibition profiles were measured and compared with each constituent antibiotic. Five 
of the dual β-lactam combinations resulted in greater than 70% survival of infected G. mellonella. Two 
combinations showed potent, enhanced efficacy versus both strains − ceftazidime + meropenem 
and aztreonam + meropenem. Comparison of PBP inhibition profiles revealed that the enhanced 
efficacy of these two dual β-lactam combinations could not be explained by more potent inhibition of 
PBPs or inhibition of a broader range of PBPs. A possible contribution to the enhanced efficacy of the 
combinations could be stimulation of innate immunity via increased haemocyte numbers compared to 
their constituent monotherapies. Combinations of β-lactam antibiotics show promise in overcoming 
MDR P. aeruginosa and are worthy of additional study and development.
Pseudomonas aeruginosa infections in healthcare settings include pneumonia, urinary tract infections and sur-
gical site infections. Risk factors include immunosuppression, prior antibiotic exposure, catheterisation and 
mechanical ventilation. Infections due to P. aeruginosa can result in bacteraemia and are associated with high 
mortality1. Effective treatment of P. aeruginosa infections can be problematic because the organism is intrinsically 
resistant, and readily acquires resistance, to multiple antibiotics. The incidence of isolation of multi-drug resistant 
(MDR) strains (defined as resistant to three or more classes of antibiotics) is increasing2.
Many antipseudomonal drugs belong to the β-lactam class of antibiotics and antipseudomonal β-lactams 
are essential for the successful treatment of P. aeruginosa infections. Resistant phenotypes often emerge dur-
ing treatment via the selection of various complex chromosomal mutations. Frequently reported mutations 
include those leading to inactivation of the porin OprD, which decreases the drug permeability of the bacterial 
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membrane, or those leading to de-repression of the intrinsic AmpC enzyme, a β-lactamase capable of hydrolysing 
penicillins and cephalosporins3. Other resistance-conferring mutations include those leading to up-regulation of 
drug efflux pumps4. Resistance can also result from the acquisition of transferable resistance genes such as those 
encoding extended-spectrum β-lactamases (ESBLs) or carbapenemases. In recent years, an increasing number 
of carbapenemase-producing P. aeruginosa outbreaks have been reported5,6. Worryingly, several of these have 
included metallo-β-lactamase (MBL) producing strains that are capable of rapidly hydrolysing carbapenems, a 
‘last-resort’ treatment option for MDR Gram-negative infections7–10. MBL production is associated with higher 
mortality rates for P. aeruginosa infections11.
To try to circumvent this problem, many resistant P. aeruginosa infections are treated with dual combina-
tions of antibiotics. The reasoning being that the simultaneous administration of two antibiotics with different 
modes of action increases the likelihood that the pathogen will be inhibited by at least one of the component 
drugs12. Receiving inappropriate initial antibiotic therapy correlates with patient mortality13, meaning that com-
bination therapy can potentially improve initial therapy. Indeed, the use of combination therapy as an initial treat-
ment has been shown in some cases to improve mortality rates for P. aeruginosa bacteraemia and pneumonia14.
Traditionally, antipseudomonal combination therapy consists of a β-lactam plus a quinolone or an aminoglyco-
side. Clinical data supporting the use of β-lactams in combination with quinolones is lacking as most studies have 
found no difference in treatment outcomes between monotherapy and combination therapy12. There is more data 
to support the efficacy of β-lactams and aminoglycosides15, however this combination is associated with toxic side 
effects16 such as kidney damage17. The evidence for combination therapy providing real therapeutic benefit for 
P. aeruginosa infections remains contentious and data from a number of studies are conflicting (reviewed in18).
It is clear that novel treatments for MDR P. aeruginosa are required urgently as no new anti-pseudomonal 
antibiotics are likely to become available in the near future. Therefore, making optimal use of the antibiotics that 
are currently available in the form of novel combinations remains a realistic solution. Dual β-lactam therapy is an 
underexplored treatment option for MDR P. aeruginosa infections. Many in vitro studies were published in the 
1980s that revealed extensive synergies between many different β-lactams against P. aeruginosa. In vivo studies, 
either in animal models or with human patients, were fewer but some also showed promise (extensively reviewed 
in19). None of these dual β-lactam combinations were developed further because at this time there was little clin-
ical need due to lower incidence of MDR pathogens and the successful administration of antibiotic monothera-
pies. However, in light of the current aforementioned problems with treating MDR P. aeruginosa, re-exploring the 
potential of β-lactam combinations could prove beneficial.
The aim of this study was to evaluate the efficacy of twenty-eight dual β-lactam combinations derived from 
eight approved drugs that each represented a major class of the β-lactams. Efficacy of each combination ther-
apy in vivo was compared with their constituent monotherapies against Galleria mellonella larvae infected with 
antibiotic-resistant strains of P. aeruginosa to identify combinations that could provide realistic future therapeutic 
options. For the most potent combinations identified, inhibition of penicillin-binding proteins (PBP) was com-
pared to monotherapies to better understand the inhibitory action.
Methods
Bacteria and growth media. Three strains were used: P. aeruginosa NCTC13437, a characterised MDR 
strain (carrying the VEB-1 ESBL and VIM-10 MBL), that is resistant to carbapenems and other β-lactam anti-
biotics and also quinolones and aminoglycosides by unknown mechanisms20. A clinical strain of P. aeruginosa 
isolated from the sputum of a patient in intensive care with a hospital-acquired pneumonia that did not respond 
to meropenem therapy. The strain is resistant to ceftazidime, imipenem and piperacillin-tazobactam and displays 
intermediate resistance to meropenem and aztreonam. The isolate was positive for the modified carbapenemase 
inhibition test and the carbapenem inactivation method by the Scottish AMR Satellite Reference Laboratory, 
Glasgow21. It was not found to possess any known carbapenemase enzymes at the Antimicrobial Resistance and 
Healthcare Associated Infections Reference Unit (AMRHAI), Public Health England, Colindale, and the antibi-
otic resistance profile was consistent with loss of the OprD porin and enhanced drug efflux. Finally, P. aeruginosa 
PA01 was provided by Dr. Olga Lomovskaya, Rempex Pharmaceuticals, USA. All strains were grown to stationary 
phase in Mueller–Hinton broth (MHB; Merck, Darmstadt, Germany) at 37 °C with shaking (at 200 rpm) over-
night to prepare inocula for antibiotic efficacy testing in vivo.
Antibiotics and G. mellonella larvae. All antibiotics were purchased from Sigma–Aldrich Ltd (Dorset, 
UK). Stock solutions of antibiotics were prepared in sterile deionized water. G. mellonella larvae were obtained 
from UK Waxworms Ltd. (Sheffield, UK).
Antibiotic susceptibility testing. Minimum inhibitory concentrations (MICs) of antibiotics against each 
of the P. aeruginosa strains were determined in 96-well microplates as previously described22. Briefly, doubling 
dilutions of each antibiotic were prepared in MHB and subsequently inoculated with 1.0 × 106 cfu/mL of P. aerug-
inosa. Microplates were incubated at 37 °C and the MIC was defined as the concentration(s) present in the first 
optically clear well after 24 h.
G. mellonella infection model. G. mellonella at their final instar larval stage were kept at room tempera-
ture in darkness. Larvae weighing within the range of 250 to 350 mg were selected for each experiment to ensure 
consistency in subsequent drug administration and were used within 1 week of receipt.
Efficacy of antibiotics alone or in combination versus G. mellonella larvae infected with the P. aeruginosa 
strains was carried out exactly as described previously22–24. Briefly, groups of 15 larvae were infected with an 
inoculum of 2.5 × 103 cfu/mL of P. aeruginosa cells (unless otherwise stated). Treatment with a single dose of each 
antibiotic alone, or dual combinations of these antibiotics, were administered 2 h post-infection. The experiments 
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were repeated in duplicate using larvae from a different batch and the data from these replicate experiments 
were pooled to give n = 30. Survival data were plotted using the Kaplan–Meier method25 and comparisons made 
between groups using the log-rank test26. In all comparisons with the negative control it was the uninfected con-
trol (rather than the unmanipulated control) that was used. Holm’s correction was applied to account for multiple 
comparisons in all tests and P ≤ 0.05 was considered significant27.
pBp detection and β-lactam titration. PBP detection and β-lactam titration were carried out as 
previously described with several minor alterations28. P. aeruginosa PAO1 cells from 1.5 ml of an overnight 
culture were harvested by centrifugation at 8,000 × g for 3 minutes at room temperature, washed in 1 mL of 
phosphate buffered saline (PBS), harvested, and resuspended in 80 μL of PBS containing 0.0001–1000 mg/L 
of aztreonam, ceftazidime or meropenem alone, or 0.0002–2000 mg/L of aztreonam + meropenem or ceftazi-
dime + meropenem. A reference sample was resuspended in 80 μl of PBS alone. The cells were incubated at 37 °C 
for 40 mins prior to harvesting and washing in PBS, harvesting and resuspension in 50 μL of PBS containing 
30 μg/mL of BOCILLIN™ FL penicillin, sodium salt (Boc-FL), a fluorescent analogue of penicillin V coupled 
with the fluorophore BODIPY FL, used to detect and label PBPs (Invitrogen, Eugene, Oregon). The cells were 
incubated at 37 °C for 30 mins, prior to harvesting and washing and final resuspension in 100 μL of PBS, and then 
sonicated (Hielscher Ultrasonic Processor (UPS200S)) for 4 × 10 second intervals (cycle = 0.5, amplitude = 40%) 
with 10 seconds cooling between each round. Following sonication, any remaining un-lysed cells were harvested 
(8,000 × g for 3 minutes at 4 °C) and the supernatant collected. The protein content was measured (NanoDrop 
2000, Thermo Scientific) and all samples were adjusted to 8 mg/mL via dilution with PBS. Next, 51 μL of each 
protein sample was mixed with 17 μL of 4 × Laemmli sample buffer (Bio-Rad, Watford, UK) supplemented with 
β-mercaptoethanol (Sigma-Aldrich, Dorset, UK) as described in the manufacturer instructions, and de-natured 
at 95 °C for 5 mins before loading 20 μL onto a 10% Tris-HCl polyacrylamide gel (Criterion™, Bio-Rad, Watford, 
UK). Proteins were separated via gel-electrophoresis for 1 hr 45 min at 120 V. The gels were then rinsed repeatedly 
with deionised water and imaged (excitation at 473 nm with a 520 nm emission filter at 50-μm pixel resolution) 
using a Typhoon FLA 7000 scanner (GE Healthcare Life Sciences, Little Chalfont, Bucks., UK).
Image J analysis and calculation of half maximal inhibitory concentration (IC50). Antibiotic PBP 
affinity profiles and IC50 values were determined as described previously28. Briefly, gel images were imported 
into Image J software (https://imagej.nih.gov/ij/download.html) and the brightness and contrast levels were 
adjusted to optimise the signal to noise ratio. The background was subtracted (rolling ball radius: 60 pixels), 
and dark noise outliers were removed (radius: 3 pixels, threshold: 50) to reduce the appearance of blemishes 
on the Typhoon scanner stage. The density of Boc-FL labelling in each protein band was quantified relative to 
the no-antibiotic reference sample using the Analyse Gels function (http://lukemiller.org/index.php/2010/11/
analyzing-gels-and-western-blots-with-image-j/). Relative Boc-FL labelling values from two independent exper-
iments were averaged and GraphPad Prism (GraphPad Software, La Jolla, CA) was used to create graphs showing 
relative % Boc-FL labelling versus β-lactam concentration. The binding affinity of each PBP for each antibiotic 
was determined by fitting a log10(inhibitor) vs. response – variable slope (four-parameter) curve to the % inhibi-
tion data from two independent experiments. IC50 values were determined using a 4-parameter logistic regression 
equation using GraFit 5.0 (Erithacus Software, East Grinstead, UK).
Determination of circulating haemocyte numbers. Groups of 15 larvae per condition were injected 
with 10 µL of PBS followed 2 h later with either PBS, aztreonam (50 mg/kg), ceftazidime (5 mg/kg) or meropenem 
(2.5 mg/kg) or aztreonam + meropenem (50 + 2.5 mg/kg) or ceftazidime + meropenem (5 + 2.5 mg/kg) to assess 
the effects of these antibiotic treatments on circulating haemocyte numbers. Unmanipulated controls were also 
included. Three larvae were randomly selected and injected with 75 µL Galleria saline29 at 5, 20.5 and 24 hours 
post-infection and haemolymph was bled into individual sterile reaction tubes and 10 µL was loaded onto an 
improved Neubauer haemocytometer and the haemocytes counted with duplicates for each sample. This experi-
ment was performed in triplicate to give n = 9 for each experimental condition.
Results
treatment of P. aeruginosa infected G. mellonella with dual combinations of a range of 
β-lactam antibiotics results in enhanced efficacy compared to monotherapy. A group of eight 
β-lactam antibiotics [meropenem (MEM), ampicillin (AMP), piperacillin (PIP), aztreonam (ATM), cefuroxime 
(CXM), cefotaxime (CTX), cefadroxil (CFR) and ceftazidime (CAZ)] that each represent a common class of 
this group of drugs were selected for screening of in vivo efficacy in dual combinations (a total of 28 combi-
nations). G. mellonella larvae were infected with P. aeruginosa NCTC13437 because it is a characterised MDR 
strain that has been used successfully to infect G. mellonella in previous studies22,24. Initial pilot experiments 
determined the efficacy of monotherapy (a single dose, administered 2 h post-infection (p.i)) with each of 
the β-lactam antibiotics listed above on G. mellonella larvae infected with a lethal dose (2.5 × 103 cells/mL) of 
P. aeruginosa NCTC13437. Four of the β-lactams administered (AMP, CXM, CTX and CFR) resulted in minimal 
therapeutic benefit to infected larvae at the highest dose tested (100 mg/kg). This result is consistent with the 
fact that these β-lactams have minimal anti-pseudomonal activity. In contrast, PIP, CAZ, ATM and MEM each 
resulted in enhanced survival of infected larvae in a dose dependent manner (data not shown). These initial 
experiments allowed the selection of doses of each individual antibiotic for subsequent study of the effect of dual 
combinations - doses of each constituent antibiotic that had minimal therapeutic benefit as monotherapies were 
selected. This approach allowed optimal identification of combinations that offer enhanced efficacy compared to 
the constituent monotherapies.
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The effect of the 28 possible dual β-lactam combinations on survival of G. mellonella larvae infected with a 
lethal dose of P. aeruginosa NCTC13437 (2.5 × 103 cells/mL) is shown in Table 1. Many of the dual combinations 
showed enhanced survival compared to either monotherapy or treatment with PBS. Five of the dual combinations 
(MEM + PIP; MEM + ATM; MEM + CAZ; PIP + ATM and ATM + CTX) resulted in greater than 70% survival 
after 96 h p.i. Markedly, all of these five most potent combination treatments contained either MEM or ATM, or 
both.
Following this initial screen, four of the best combinations were studied in greater detail and confirmed signif-
icantly enhanced efficacy of MEM + CAZ, ATM + CTX, ATM + MEM and ATM + PIP compared to sham treat-
ment with either PBS or each constituent monotherapy (Fig. 1). To test the potency of the above combinations, 
the therapeutic benefit of each combination treatment was determined versus G. mellonella larvae infected with 
increasing inoculum sizes of P. aeruginosa NCTC13437 (Fig. 2). As shown before, each of the four combination 
treatments significantly enhanced survival of larvae infected with 2.5 × 103 c.f.u/mL 96 h p.i. Increasing the num-
ber of infecting bacteria 10-fold (2.5 × 104 c.f.u/mL), 100-fold (2.5 × 105 c.f.u/mL) or 1000-fold (2.5 × 106 c.f.u/mL) 
resulted in an inoculum-dependent reduction in survival for all combinations tested. Notably, all four combina-
tions still had some therapeutic benefit 96 h p.i with 2.5 × 105 c.f.u/mL and treatment with ATM + MEM resulting 
in some survival after infection with the highest inoculum tested - 2.5 × 106 c.f.u/mL (Fig. 2).
Therapy
Antibiotic(s) or 
PBS control
Dose
(mg/kg)
% survival in 
vivo 96 h p.i
Sham treatment PBS 10 μL PBS 0
Monotherapy
MEM 2.5 3
AMP 100 0
PIP 100 30
ATM 50 23
CXM 100 7
CTX 100 27
CFR 100 0
CAZ 5 10
Dual combination 
therapy
MEM + AMP 2.5 + 100 33
MEM + PIP 2.5 + 100 73*
MEM + ATM 2.5 + 50 87*
MEM + CXM 2.5 + 100 60*
MEM + CTX 2.5 + 100 40
MEM + CFR 2.5 + 100 33
MEM + CAZ 2.5 + 5 80*
AMP + PIP 100 + 100 40
AMP + ATM 100 + 50 47
AMP + CXM 100 + 100 0
AMP + CTX 100 + 100 7
AMP + CFR 100 + 100 0
AMP + CAZ 100 + 5 0
PIP + ATM 100 + 50 73*
PIP + CXM 100 + 100 20
PIP + CTX 100 + 100 53
PIP + CFR 100 + 100 7
PIP + CAZ 100 + 5 13
ATM + CXM 50 + 100 53
ATM + CTX 50 + 100 80*
ATM + CFR 50 + 100 47
ATM + CAZ 50 + 5 60
CXM + CTX 100 + 100 27
CXM + CFR 100 + 100 0
CXM + CAZ 100 + 5 7
CTX + CFR 100 + 100 7
CTX + CAZ 100 + 5 40
CFR + CAZ 100 + 5 0
Table 1. Initial screen of the efficacy of twenty-eight dual β-lactam combination treatments against G. 
mellonella larvae infected with a lethal dose of P. aeruginosa NCTC13437. One dose of each monotherapy 
or dual combination was administered 2 h p.i. and survival measured 96 h p.i. *Indicates significantly 
enhanced survival compared to both monotherapies (p < 0.05, log rank test with Holm correction for multiple 
comparisons). n = 15.
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In summary, G. mellonella larvae infected with an MDR strain of P. aeruginosa were successfully treated with 
dual combinations of β-lactam antibiotics.
Dual combinations of β-lactam antibiotics also result in enhanced survival of G. mellonella 
larvae infected with an alternative antibiotic resistant, clinical isolate of P. aeruginosa. To 
determine if the same potent β-lactam combinations resulted in enhanced efficacy versus an alternative 
antibiotic-resistant P. aeruginosa strain, the therapeutic effect of the combinations was tested on larvae infected 
with a carbapenem-resistant clinical isolate of P. aeruginosa. As before, initial experiments measured the effect 
of β-lactam monotherapies to identify doses of each drug that resulted in minimal therapeutic benefit to infected 
larvae that could then be administered in the combination studies (data not shown). The same dual combinations 
of β-lactams administered to P. aeruginosa NCTC13437 (Table 1) were administered to larvae infected with 
the clinical isolate. Once again, many combinations resulted in enhanced efficacy compared to their constitu-
ent monotherapies and the four best combination treatments (MEM + CAZ, ATM + MEM, MEM + PIP and 
MEM + CTX) are shown in Fig. 3. As before, these four most potent combination treatments contained either 
MEM or ATM, or both. Notably, two combinations showed potent, enhanced efficacy versus both strains of P. 
aeruginosa used in this study - MEM + CAZ and ATM + MEM and subsequent studies focused on these two 
combinations.
To conclude, the significantly enhanced efficacy of dual combinations of β-lactam antibiotics observed previ-
ously was replicated against an unrelated, antibiotic-resistant clinical isolate of P. aeruginosa.
The enhanced efficacy of the MEM + CAZ and ATM + MEM combinations cannot be explained 
by increased inhibition of a wider range of P. aeruginosa PBPs. A primary hypothesis explain-
ing why β-lactam combinations can offer enhanced efficacy is the broadened spectrum of PBPs that could be 
inhibited by administering multiple drugs with different PBP affinities [reviewed in19]. Thus, the effect of the 
most potent combinations on inhibition of P. aeruginosa PBPs was compared with the effect of the constituent 
monotherapies. For this work, P. aeruginosa PA01 was used rather than the antibiotic-resistant strains employed 
previously because the presence of VEB-1 and VIM-10 in NCTC13437, could interfere with the PBP-labelling 
Figure 1. Effect of treatment with β-lactam monotherapies or dual combinations on survival of G. mellonella 
larvae infected with 2.5 × 103 cfu/mL P. aeruginosa NCTC13437 and treated with PBS or: (a) MEM (2.5 mg/kg), 
CAZ (5 mg/kg) or MEM + CAZ (2.5 + 5 mg/kg); (b) ATM (50 mg/kg), CTX (100 mg/kg) or ATM + CTX 
(50 + 100 mg/kg); (c) ATM (50 mg/kg), MEM (2.5 mg/kg) or ATM + MEM (50 + 2.5 mg/kg); (d) ATM 
(50 mg/kg), PIP (100 mg/kg) or ATM + PIP (50 + 100 mg/kg). A single dose of the antibiotic treatments was 
administered 2 h p.i. The uninfected group represents larvae sham-infected with sterile PBS and treated with 
sterile PBS. *Indicates significantly enhanced survival compared to both monotherapies (p < 0.05, log rank test 
with Holm correction for multiple comparisons); n = 30 (pooled from duplicate experiments).
6Scientific RepoRts |          (2019) 9:9098  | https://doi.org/10.1038/s41598-019-45550-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
assay that uses Bocillin-FL (Boc-FL), a fluorescent analogue of penicillin V, to measure antibiotic-dependent 
inhibition of PBPs.
Boc-FL has been used to study the PBPs of a range of bacteria, including P. aeruginosa30–33. Live P. aeruginosa 
PA01 cells were incubated with increasing concentrations of CAZ, MEM or ATM and the dual combinations of 
MEM + CAZ or ATM + MEM. After incubation, PBPs that had not been bound by the single antibiotics or com-
binations were labelled using Boc-FL. The PBPs were separated by SDS-PAGE and the affinity of the β-lactams or 
the combinations for each PBP was quantified by measuring Boc-FL labelling relative to an unexposed control. 
Experiments were run in duplicate and an example gel image for each of the drug treatments and their effect on 
PBP labelling by Boc-FL is shown in Fig. 4. Seven gel bands corresponding to PBP1a, PBP1b, PBP2, PBP3a, PBP4, 
PBP5 and PBP7 were identified. Identification of the P. aeruginosa PA01 PBPs was based on molecular weight and 
comparison of the electrophoretic pattern with previously published studies30–33.
Dose-dependent inhibition of Boc-FL labelling of PBPs upon exposure to increasing concentrations of the dif-
ferent β-lactam treatments can be observed on the gels and clear differences in PBP affinities between the different 
treatments can be seen. For example, there is visible loss of PBP4 Boc-Fl labelling in cells exposed to 10−3 mg/L of 
MEM that is not seen with either ATM or CAZ at the same concentration (Fig. 4). Quantitative analysis of Boc-FL 
labelling of PBPs was performed using densitometry of the gel bands representing each of the P. aeruginosa PBPs. 
The density of the PBP bands from control cells not exposed to any β-lactams were set at 100% and the densities 
of the PBP bands on the gel after exposure to increasing concentrations of the single β-lactams, or the two dual 
combinations, were expressed as a percentage of the control. Thus, decreasing Boc-FL labelling of PBPs results 
in a reduction in gel band densities and indicates increasing inhibition of PBPs by the β-lactam regimen being 
tested. Figure 5 shows the relative % of Boc-FL labelling against β-lactam concentration for each of the PBPs. 
Exposure to increasing concentrations of ATM caused an initial increase in Boc-FL labelling of PBP1a and PBP1b 
relative to the control before inhibition occurred. This effect has been documented before when ATM was shown 
to cause an increase in labelling of these PBPs in Escherichia coli28. No increase in protein levels were detected and 
the increase in labelling remains unexplained.
Differences in the affinities of the β-lactam regimens for PBPs can be observed. For example, MEM is the most 
potent inhibitor of PBP1a with >50% inhibition of Boc-FL labelling at 0.1 mg/L compared to approximately 25% 
inhibition for CAZ, and no apparent inhibition for ATM, at the same concentration. Similarly, at 0.1 mg/L MEM 
is clearly a more potent inhibitor of PBP1b than either ATM or CAZ. With PBP2 and 3a obvious differences 
between the different β-lactam treatments inhibition profiles were indiscernible. The most significant difference 
Figure 2. Survival of G. mellonella larvae 96 h p.i with increasing inoculum sizes (2.5 × 103, 104, 105 or 106 cfu/mL) 
of P. aeruginosa NCTC13437 and treated with PBS or dual β-lactam combinations of: (a) MEM + CAZ 
(2.5 + 5 mg/kg); (b) ATM + CTX (50 + 100 mg/kg); (c) ATM + MEM (50 + 2.5 mg/kg); (d) ATM + PIP 
(50 + 100 mg/kg). A single dose of the antibiotic treatments was administered 2 h p.i. The uninfected group 
represents larvae sham-infected with sterile PBS and treated with sterile PBS. Error bars represent the 
mean ± SEM of replicate experiments.
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in affinity between the β-lactams was observed for PBP4. At 1 mg/L, MEM reduced Boc-Fl binding by 100% 
compared to an approximate 25% and 10% reduction by CAZ and ATM respectively. MEM also appeared to be 
a more potent inhibitor of PBP5 than either CAZ or ATM. None of the β-lactam treatments inhibited PBP7 in a 
dose-dependent manner and >50% reduction in Boc-Fl labelling was not observed at any concentration tested. 
Notably, the inhibition profiles of the dual combinations ATM + MEM and CAZ + MEM appeared to closely 
match that of MEM alone but without any obvious enhancement of affinity for any of the PBPs. In fact, for PBP5, 
the combinations did not inhibit as potently as MEM alone despite having a more potent inhibitory effect than 
either ATM or CAZ.
To describe the PBP affinity profile of each of the β-lactam treatments, half maximal inhibitory concentration 
(IC50) values were determined and are shown in Table 2. Dose-response curves were fitted to the data describing 
the inhibition of each PBP by each of the β-lactam treatments tested and IC50 values calculated. The IC50 values 
provide insight into the preferential PBP targets for each of the treatments and relating the IC50 concentration 
with the MIC of P. aeruginosa PA01 also indicates if the PBP inhibition is likely to contribute to the antibacterial 
effect of the drug. The MIC values (mg/L) for P. aeruginosa PA01 were: ATM (1–2); CAZ (0.5–1) and MEM (1). 
Thus, ATM was selective for PBP1a and PBP1b and the IC50 values for both PBPs were less than the MIC for this 
drug. CAZ was selective for PBP1a and PBP2 and IC50 values for both PBPs were lower than the MIC, particularly 
that for PBP2. MEM was clearly the most potent β-lactam tested in terms of PBP affinity, showing selectivity for 
PBP1b and PBP4 but the IC50 values for PBP1a, 1b, 2, 4 and 5 were all lower than the MIC. Remarkably, none of 
the PBP IC50 values for the dual β-lactam combinations, both of which contained MEM, were lower than those 
obtained for MEM alone. With the exception of PBP4, the IC50 values were all higher than those calculated for 
MEM. From the dose-response curves, the % inhibition of each PBP by each individual antibiotic at their MIC 
was calculated and is shown in Table 3. This data supports the previous observations and implies that inhibition of 
PBPs by a combination of MEM with ATM or CAZ is not likely to be greater than the degree of inhibition induced 
upon exposure to MEM alone.
In summary, the enhanced efficacy of the dual β-lactam combinations ATM + MEM and CAZ + MEM against 
P. aeruginosa in vivo is not due to more potent inhibition of PBPs or inhibition of a broader range of PBPs.
Figure 3. Effect of treatment with β-lactam monotherapies or dual combinations on survival of G. mellonella 
larvae infected with 2.5 × 103 cfu/mL of a carbapenem-resistant clinical isolate of P. aeruginosa and treated with 
PBS or: (a) MEM (0.5 mg/kg), CAZ (0.5 mg/kg) or MEM + CAZ (0.5 + 0.5 mg/kg); (b) MEM (0.5 mg/kg),  
PIP (50 mg/kg) or MEM + PIP (0.5 + 50 mg/kg); (c) ATM (2.5 mg/kg), MEM (0.5 mg/kg) or ATM + MEM 
(2.5 + 0.5 mg/kg); (d) MEM (0.5 mg/kg), CTX (100 mg/kg) or MEM + CTX (0.5 + 100 mg/kg). A single dose 
of the antibiotic treatments was administered 2 h p.i. The uninfected group represents larvae sham-infected 
with sterile PBS and treated with sterile PBS. *Indicates significantly enhanced survival compared to both 
monotherapies (p < 0.05, log rank test with Holm correction for multiple comparisons); n = 30 (pooled from 
duplicate experiments).
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exposure of uninfected G. mellonella larvae to the dual β-lactam combinations ATM + MEM 
and CAZ + MEM stimulates an increase in circulating haemocyte numbers. Because the enhanced 
efficacy of the dual β-lactam combinations cannot be explained by increased inhibition of PBPs, alternative 
mechanisms were considered. In a previous study using G. mellonella, administration of antibiotics alone to 
uninfected larvae induced a significant increase in the number of circulating haemocytes compared to larvae 
injected with PBS34. Thus, perhaps the enhanced efficacy of the dual β-lactam combinations could be explained 
by antibiotic-mediated stimulation of innate immunity in a similar fashion.
The effect of administration of ATM, CAZ and MEM alone and ATM + MEM or CAZ + MEM to uninfected 
G. mellonella larvae on the numbers of circulating haemocytes was measured using microscopy (Fig. 6). Larvae 
were mock-infected with sterile PBS then injected 2 h later with PBS, ATM (50 mg/kg), CAZ (5 mg/kg) or MEM 
(2.5 mg/kg), or combinations of ATM + MEM or CAZ + MEM at the same doses as the single drugs. Relative 
to PBS treatment, exposure to ATM resulted in an initial, transient increase in haemocyte numbers after 5 h. 
Exposure to MEM alone also resulted in an increase but less than ATM with the maximum increase occurring 
after 24 h. In contrast, CAZ alone resulted in only a minor increase in haemocyte number after 24 h. Notably, 
exposure to either of the dual β-lactam combinations resulted in larger, more significant increases in circulating 
haemocytes than the individual drugs (Fig. 6).
In summary, antibiotic-mediated stimulation of innate immunity in the form of increased haemocyte num-
bers could contribute to the enhanced efficacy of the β-lactam combinations in vivo.
Figure 4. Titration of P. aeruginosa PA01 PBPs by ATM, CAZ or MEM, or ATM + MEM, or CAZ + MEM. 
Live cells were treated with 10-fold increasing concentrations of each of the β-lactam treatments listed above 
prior to labelling of PBPs with a fluorescent analogue of penicillin V (Boc-FL). Cells were sonicated and the 
protein content in each sample equalised to 8 mg/mL. PBPs were separated via SDS-PAGE on 10% Tris-HCl 
polyacrylamide gels and visualised using a fluorescent scanner (excitation at 473 nm with a 520 nm emission 
filter). Gel images shown are representative images from duplicate experiments.
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Discussion
Effective β-lactam combinations that target P. aeruginosa have been identified in previous studies but were never 
developed further for clinical administration principally due to lack of need (reviewed in19). However, the rise 
in problematic MDR Gram-negative infections with few treatment options means that β -lactam combinations 
Figure 5. Quantitation of Boc-FL labelling of each P. aeruginosa PA01 PBP gel band in the presence of 
increasing concentrations of either ATM, CAZ or MEM, or the dual combinations of ATM + MEM or 
CAZ + MEM. The density of Boc-FL labelling of each PBP gel band was quantified relative to the no-antibiotic 
exposure reference sample and expressed as %. Relative Boc-FL labelling values from two independent 
experiments were averaged and error bars represent the mean ± SEM.
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could be a potential solution. This study presents evidence that dual combinations of β-lactams offer enhanced 
efficacy against infections caused by MDR P. aeruginosa in an invertebrate model of systemic infection. The two 
most potent dual combinations identified in this study (meropenem with aztreonam or ceftazidime) have not 
been reported previously. The presence of a carbapenem (meropenem) in these effective combinations is notable 
because much of the past research on β-lactam combinations was carried out in the 1980’s and data is lacking on 
the use of carbapenems in combinations versus P. aeruginosa, particularly in vivo. Furthermore, the majority of 
the previous studies on the efficacy of β-lactam combinations were not carried out on MDR strains of P. aerugi-
nosa19. Thus, the effective combinations reported here could represent real options for therapeutic intervention 
against resistant P. aeruginosa and merit further investigation in mammalian infection models and ultimately 
patients. This conclusion is supported by a number of studies that have highlighted successful application of dual 
β-lactam combinations to treat patients infected with MDR, and carbapenemase carrying, strains of Klebsiella 
pneumoniae35–38.
Many of the potent β-lactam combinations that were identified in this study included the synthetic, monocy-
clic β-lactam, aztreonam. This observation is supported by many in vitro studies that report significant synergy 
versus P. aeruginosa between aztreonam and third or fourth generation cephalosporins, such as ceftazidime and 
cefepime19,39. The inclusion of aztreonam in dual combinations versus MDR Gram-negative bacteria that possess 
carbapenemases is logical because the drug is not hydrolysed by MBLs. However, aztreonam is susceptible to 
Beta-lactam 
treatment
IC50 (mg/L)
PBP1a PBP1b PBP2 PBP3a PBP4 PBP5 PBP7
ATM 0.904 ± 0.283 0.816 ± 0.543 4.56 ± 3.746 >1000 5.449 ± 2.035 >1000 >1000
CAZ 0.469 ± 0.159 4.48 ± 4.33 1.329 ± 1.134 >1000 8.022 ± 2.19 >1000 >1000
MEM 0.105 ± 0.053 0.037 ± 0.009 0.744 ± 1.251 6.034 ± 4.878 0.003 ± 0.0002 0.3697 ± 0.271 >1000
ATM + MEM 0.158 ± 0.068 0.067 ± 0.022 15.884 ± 19.289 >1000 0.004 ± 0.0011 5.498 ± 4.649 >1000
CAZ + MEM 0.631 ± 0.326 0.082 ± 0.042 17.987 ± 26.859 >1000 0.004 ± 0.0005 6.724 ± 2.874 >1000
Table 2. IC50 values (± the standard error determined in GraFit 5.0) for P. aeruginosa PAO1 PBPs for the 
single antibiotic treatments (ATM, CAZ or MEM) and the dual combination treatments (MEM + ATM and 
MEM + CAZ). Underlining shows lowest IC50 for each β-lactam treatment − indicating selectivity.
Beta-lactam 
treatment
% Inhibition of Boc-FL labelling at MIC (1 mg/L)
PBP1a PBP1b PBP2 PBP3a PBP4 PBP5 PBP7
ATM 65.28 69.07 18.13 0 9.97 0 0
CAZ 76.49 28.65 50.1 0 21.64 0 0
MEM 86.03 97.5 52.59 14.76 100 54.73 0
Table 3. Degree of inhibition of P. aeruginosa PAO1 PBPs at the approximate MIC (1 mg/L) of each of the 
individual antibiotics.
Figure 6. Effect of exposure to β-lactams on overall numbers of circulating G. mellonella haemocytes. Larvae 
were sham-infected with PBS and then 2 h p.i administered either PBS, ATM (50 mg/kg), CAZ (5 mg/kg) or 
MEM (2.5 mg/kg), or combinations of ATM + MEM or CAZ + MEM at the same doses as the single drugs. 
Numbers of haemocytes in the larval haemolymph were then counted at 5, 20.5 and 24 h p.i. Haemocyte 
numbers are presented relative to larvae sham-infected with PBS and subsequently treated with PBS. Data is 
from 9 larvae per time-point showing mean ± SEM.
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hydrolysis by most serine ESBLs and because many MDR pathogens carrying an MBL also possess ESBLs, azt-
reonam will need to be administered in combination with the novel β-lactamase inhibitor avibactam (reviewed 
in40). Unfortunately, avibactam is only a weak inhibitor of Ambler class B MBLs such as VIM-10 that is carried by 
P. aeruginosa NCTC 13437 used in this study and is thus unlikely to be part of an effective therapy41.
Definitive studies on the actual mechanism underpinning β-lactam synergy are lacking. However, the prin-
cipal hypothesis is that a broader spectrum of PBPs can be inhibited by combining β-lactams with different PBP 
affinity profiles. While β-lactams confer their antibiotic activity through PBP inhibition, individual antibiotics 
differ in their affinities for each of the bacterial PBPs. Therefore, a combination treatment with two β-lactams 
each with differing PBP binding profiles could provide broader PBP inhibition and thus collectively enhance their 
inhibitory effect and efficacy in vivo19. Adding to this, an alternative ‘shielding’ hypothesis potentially explains 
why dual β-lactams are more effective against resistant strains possessing ESBLs or MBLs - one of the component 
β-lactams could bind preferentially, or with higher affinity, to the β-lactamase enzyme, thus sequestering the 
hydrolytic capacity of the enzyme, and allowing the other component β-lactam to bind to its target PBP(s) more 
effectively. For example, Lister et al.42. revealed that aztreonam enhanced the activity of cefepime versus P. aerug-
inosa strains expressing chromosomal AmpC β-lactamases. A possible explanation for this was the high affinity 
aztreonam has for the active site of some β-lactamases, such as AmpC enzymes, meaning that it could also act as 
an inhibitor thus permitting cefepime to act unhindered43.
In this work, a novel method first used to study Escherichia coli PBPs was applied to P. aeruginosa28. This 
method uses Boc-FL to label PBPs in living cells rather than purified membranes with the advantage of avoiding 
any negative effects membrane preparation could have on PBP activity44. Using this method, all P. aeruginosa 
PBPs were identified with the exception of PBP3. PBP3 was not seen because stationary-phase cells were used in 
these experiments. PBP3 is expressed during the exponential-phase of growth and is down-regulated upon entry 
to stationary phase when cells switch to PBP3a expression45. Stationary phase cells were used to be consistent 
with the earlier experiments measuring efficacy of the various β-lactam treatments on G. mellonella larvae that 
were infected with stationary phase cells. PBP3 is essential for growth of P. aeruginosa, while the other PBPs can 
be individually deleted46. Many antipseudomonal β-lactams have been reported to preferentially bind to PBP3 
including the drugs used in this study – aztreonam, ceftazidime and meropenem30. Unfortunately, because PBP3 
was not detected here, any differences between the inhibition of PBP3 by the individual β-lactams and the dual 
combinations were not compared. However, if the previous studies are correct, and aztreonam, ceftazidime and 
meropenem all have high affinity for PBP3, it could be argued that combinations of these drugs would be unlikely 
to result in further significant inhibition that could explain the enhanced efficacy of the combinations observed 
in vivo.
PBP1a and PBP2 are thought to be relevant β-lactam targets as simultaneous mutation of their transpeptidase 
domain results in cells that show reduced fitness46. The low molecular weight (LMW) PBPs are not considered 
to be important targets of the β-lactams since simultaneous deletion of PBP4, PBP5 and PBP7 has no significant 
effect on growth rate or cell morphology47.
The calculated PBP affinities of the β-lactams used in this work with those reported previously were generally 
consistent but with some notable exceptions19. For example, ceftazidime was observed to inhibit PBP2 unlike pre-
vious studies30,31. Also, meropenem inhibited PBP5, and particularly PBP4, with high affinity and was also a more 
potent inhibitor of PBP1b than reported previously19,30. These discrepancies could be due to the use of different 
PBP labelling methods between this and previous studies as discussed above. Meropenem was found to inhibit 
multiple PBPs unlike aztreonam or ceftazidime. In addition, comparison of PBP inhibition at the MIC of all three 
drugs revealed that meropenem was also a more potent inhibitor of the PBPs that were preferentially targeted by 
either aztreonam or ceftazidime. This broad-spectrum of coverage of PBPs could explain why meropenem is the 
more potent antibiotic than the other drugs investigated when employed as a monotherapy.
The dual combinations of meropenem with either aztreonam or ceftazidime did not decrease the IC50 values 
below those that were calculated for meropenem alone. In fact, the combinations had increased IC50 values for all 
the PBPs compared with meropenem. Similarly, neither of the combinations resulted in broader coverage of over-
all PBPs inhibited compared to meropenem. Thus, the hypothesis that a broader spectrum of PBPs are inhibited 
by combining β-lactams with different PBP affinity profiles can be discounted as an explanation for the enhanced 
efficacy of these particular β-lactam combinations in vivo. Perhaps the ‘shielding’ hypothesis discussed previously 
offers the more likely explanation why PBP-inhibiting drug combinations show enhanced efficacy in vivo against 
β-lactamase carrying MDR strains of P. aeruginosa and additional studies will be required to test this hypothesis.
A further possible mechanism that could partly explain the enhanced efficacy of the β-lactam combinations 
in vivo is the increase in haemocyte numbers that was induced in response to exposure to the antibiotic combi-
nations compared to the monotherapies. Notably, a direct correlation between increased numbers of circulating 
haemocytes and enhanced survival of G. mellonella larvae infected with fungal pathogens has been observed48. 
The immunomodulatory effects of antibiotics on human phagocytes can include both enhancement and suppres-
sion of phagocytosis (reviewed in49). β-lactams were previously shown to have pro-inflammatory properties by 
upregulating interleukin expression in murine macrophages50 and by stimulating macrophage phagocytosis51. 
Supporting the antibiotic-mediated increase in circulating haemocytes reported here, a similar immune-priming 
effect upon exposure to different antimicrobials has been shown in G. mellonella larvae previously34,52,53.
Irrespective of the precise inhibitory action, it is clear that combinations of PBP-inhibiting drugs show great 
promise in overcoming MDR P. aeruginosa and are worthy of additional study and development. Before dual 
β-lactam therapy can be optimised for MDR P. aeruginosa infections, it will be important to undertake additional 
studies to determine the contributing mode(s) of action in order to maximise bactericidal activity and prevent 
resistance development.
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Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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